-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EGzAKNHDCLlWwDIAnuxEaOUj9DQ6/pdNcICUODvazhA+6MkUCytfx7gec6G2k34f yLVrEhBkBoLJbfBUHVfogQ== 0001341004-09-002369.txt : 20100729 0001341004-09-002369.hdr.sgml : 20100729 20091130163711 ACCESSION NUMBER: 0001341004-09-002369 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20091130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENZON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000727510 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222372868 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 685 ROUTE 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908 541 8671 MAIL ADDRESS: STREET 1: 685 ROUTE 202/206 STREET 2: ATT: GENERAL COUNSEL CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICALS INC DATE OF NAME CHANGE: 20021211 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICAL INC DATE OF NAME CHANGE: 20021210 FORMER COMPANY: FORMER CONFORMED NAME: ENZON INC DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm enzon.htm
 
 
Enzon Pharmaceuticals, Inc.
685 Route 202/206
Bridgewater, NJ 08807

November 30, 2009

VIA EDGAR TRANSMISSION

John L. Krug, Esq.
Senior Counsel
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C.  20549-4720
  

 
Re:
Enzon Pharmaceuticals, Inc.
   
Preliminary Proxy Statement
   
Filed on November 23, 2009
    File No. 000-12957
 


Dear Mr. Krug:

In response to your request in the letter dated November 25, 2009 relating to the above-referenced filing on Schedule 14A, Enzon Pharmaceuticals, Inc. (the "Company") hereby acknowledges the following:

 
1.
The Company is responsible for the adequacy and accuracy of the disclosure in the Company's filing;
     
 
2.
Comments from the Staff (the "Staff") of the Securities and Exchange Commission (the "Commission") or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and
     
 
3.
The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 
Very truly yours,
  
     
 
ENZON PHARMACEUTICALS,  INC.
     
     
 
By:      
/s/ Craig A. Tooman
  
 
Name:   
Craig A. Tooman
 
Title:    
EVP Finance and CFO


cc:
Susanne Hayes, Esq., Securities and Exchange Commission
 
Daniel Greenspan, Esq., Securities and Exchange Commission
 
Daniel E. Stoller, Esq., Skadden, Arps, Slate, Meagher & Flom LLP
 
Richard J. Grossman, Esq., Skadden, Arps, Slate, Meagher & Flom LLP

-----END PRIVACY-ENHANCED MESSAGE-----